
Entering the European market is not one establishment decision but several. Some roles must sit inside the EEA, some inside a specific Member State, some[…]

Almost every European country sets medicine prices partly by looking at what other European countries pay. That single fact turns a sequence of national pricing[…]

Greece is a full EU Member State with a mature regulatory authority, high pharmaceutical consumption and a price that travels well beyond its borders. It[…]

Pharmacovigilance inspections are not rare events to be prepared for once. Guidance expects marketing authorisation holders to be inspected at least once every four years,[…]

Greece does not pre-approve your promotional material — but it does require you to file it, it bans advertising reimbursed medicines to the public, and[…]

Labelling is the part of the dossier that companies leave until last and then discover cannot be rushed. User testing takes weeks and needs real[…]

Most marketing authorisations are lost through inattention rather than refusal. Two provisions do the work: the renewal, which requires a positive act nine months before[…]

A marketing authorisation transfer looks like paperwork and behaves like a project. The regulatory step itself is fast — the European Medicines Agency must issue[…]

Most finished medicines placed on the Greek and EU market rely on active substances manufactured outside the Union. The Falsified Medicines Directive closed that door[…]

The EU has three distinct tools for getting a medicine that addresses an unmet medical need to patients sooner: PRIME support during development, accelerated assessment[…]